Literature DB >> 16951410

Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices.

Katerina Jandová1, Dennis Päsler, Leandro Leite Antonio, Claudia Raue, Shengbo Ji, Marleisje Njunting, Oliver Kann, Richard Kovács, Heinz-Joachim Meencke, Esper A Cavalheiro, Uwe Heinemann, Siegrun Gabriel, Thomas-Nicolas Lehmann.   

Abstract

Overexpression of drug efflux pumps at the blood brain barrier (BBB) has been suggested to be one important factor contributing to drug resistance in epilepsy. This would imply that resected brain tissue of drug-resistant patients is drug-sensitive in absence of the BBB. Here we studied the effects of carbamazepine (CBZ) at therapeutically relevant concentration on epileptiform activity electrophysiologically recorded in acute hippocampal slices of patients with mesial temporal lobe epilepsy (MTLE; 28 patients, 49 slices) or extra-hippocampal tumours (tumour; 6 patients, 11 slices). Epileptiform activity was induced by hilar stimulation (0.067 Hz) during elevation of extracellular potassium concentration ([K(+)](o)) and remained self-sustained in presence of 10-12 mM [K(+)](o). Quantitative analysis of data revealed that epileptiform activity in tissue of tumour-patients was predominantly suppressed by CBZ, indicating that the 'epilepsy model' used is CBZ-sensitive. In contrast, epileptiform activity in tissue of drug-resistant MTLE patients was resistant to CBZ in 82% of patients, partially suppressed in 11% and completely suppressed in 7%. The effects of CBZ in tissue of MTLE patients did not depend on the type of activity, hippocampal pathology, excitability of the tissue, or equilibration time of the drug. Considering that CBZ has direct access to all compartments of the slice, our results suggest that CBZ-resistance mechanisms are located within the parenchyma of the dentate gyrus and contribute to drug resistance in the majority of MTLE patients. BBB-located drug-resistance mechanisms per se may play a minor role in this region, because CBZ-sensitivity was only observed in 7% of CBZ-resistant patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951410     DOI: 10.1093/brain/awl218

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  24 in total

1.  New developments in antiepileptic drug resistance: an integrative view.

Authors:  Dieter Schmidt; Wolfgang Löscher
Journal:  Epilepsy Curr       Date:  2009 Mar-Apr       Impact factor: 7.500

2.  Intrinsic severity as a determinant of antiepileptic drug refractoriness.

Authors:  Michael A Rogawski; Michael R Johnson
Journal:  Epilepsy Curr       Date:  2008 Sep-Oct       Impact factor: 7.500

3.  Net worth of networks: specificity in anticonvulsant action.

Authors:  Calvin J Schneider; Ivan Soltesz
Journal:  Epilepsy Curr       Date:  2015 Jan-Feb       Impact factor: 7.500

4.  Homeostatic bioenergetic network regulation - a novel concept to avoid pharmacoresistance in epilepsy.

Authors:  Detlev Boison; Susan A Masino; Jonathan D Geiger
Journal:  Expert Opin Drug Discov       Date:  2011-07       Impact factor: 6.098

5.  DREADDs suppress seizure-like activity in a mouse model of pharmacoresistant epileptic brain tissue.

Authors:  N Avaliani; M Andersson; A H Runegaard; D Woldbye; M Kokaia
Journal:  Gene Ther       Date:  2016-07-14       Impact factor: 5.250

Review 6.  Issues related to development of new antiseizure treatments.

Authors:  Karen S Wilcox; Tracy Dixon-Salazar; Graeme J Sills; Elinor Ben-Menachem; H Steve White; Roger J Porter; Marc A Dichter; Solomon L Moshé; Jeffrey L Noebels; Michael D Privitera; Michael A Rogawski
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

7.  Glutamatergic pre-ictal discharges emerge at the transition to seizure in human epilepsy.

Authors:  Gilles Huberfeld; Liset Menendez de la Prida; Johan Pallud; Ivan Cohen; Michel Le Van Quyen; Claude Adam; Stéphane Clemenceau; Michel Baulac; Richard Miles
Journal:  Nat Neurosci       Date:  2011-04-03       Impact factor: 24.884

8.  Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats.

Authors:  Ajay K Srivastava; H Steve White
Journal:  Epilepsy Res       Date:  2012-11-14       Impact factor: 3.045

9.  Standard antiepileptic drugs fail to block epileptiform activity in rat organotypic hippocampal slice cultures.

Authors:  K Albus; A Wahab; U Heinemann
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

10.  Diabetes mellitus contributes to carbamazepine resistance in patient with trigeminal neuralgia.

Authors:  Anke Zhang; Wenbo Zhang; Houshi Xu; Chenqi Guo; Ling Yuan; Yuanzhi Xu; Jie Ren; Lingzhao Min; Qiuyang Sun; Meiqing Lou; Lili Wei; Shaojian Lin
Journal:  Neurosurg Rev       Date:  2020-04-24       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.